Pipeline
Techfields is dedicated to improving the clinical development of therapeutics. Our technology creates prodrugs from safe, clinically approved drugs to improve penetration into target tissues.
Our current clinical programs include X0002, indicated for pain related to osteoarthritis (knee and back), and TF0023, indicated for the hyperinflammatory state related to the complications from COVID-19 infection.
IND-enabling work has also been completed on a product indicated for depression. Several more products are in the early pipeline, including applications indicated for Parkinson’s disease, Alzheimer’s disease, antibiotic resistance, and sexual dysfunction.
Product | Indications | Global Rights | Preclinical | Phase I | Phase II | Phase III |
---|---|---|---|---|---|---|
X0002 |
| | ||||
TF0023 |
| | ||||
TF0023 |
| | ||||
TF0066 |
| | ||||
TF0062 |
| | ||||
TF0068 |
| |
X0002
- Pain from osteoarthritis (OA)
Preclinical Phase I Phase II Phase III
TF0023
- Covid-19 (Therapeutic)
Preclinical Phase I Phase II Phase III
TF0023
- Recovery of stroke and
heart attack - Pulmonary embolism
- Chronic heart failure
(CHF)
Preclinical Phase I Phase II Phase III
TF0066
- Neuropathic pain
- Anti-depression
Preclinical Phase I Phase II Phase III
TF0062
- Anti-obesity
Preclinical Phase I Phase II Phase III
TF0068
- Parkinson
Preclinical Phase I Phase II Phase III